Cerus Q2 product revenue up 16% to $45M; raises FY2024 guidance to $175-178M

CERUS CORP

2024-Q2 EPS reported -$0.08

Q2 product revenue $45.1M (+16% YoY); total revenue $50.5M (+6% YoY).
GAAP net loss narrowed to $5.8M ($0.03/share) from $13.3M loss in Q2 2023.
Non-GAAP adjusted EBITDA turned positive at $0.8M (vs -$4.7M prior year).
Full-year product revenue guidance raised to $175-178M; IFC guidance unchanged at $8-10M.
Canadian Blood Services achieved 100% INTERCEPT platelet adoption.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.